L-Lysine 400 L-Lysine HCL Tablet 400 mg
L-Lysine 400 L-Lysine HCL Tablet 400 mg, NPN 80000609: natural health product licensed in Canada. Medicinal ingredients: Acide (2S)-2,6-diaminohexanoïque.
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Acide (2S)-2,6-diaminohexanoïque | 400 mg | Not calculated |
Non-medicinal ingredients
Cellulose, microcristalline, Povidone, Stéarate de magnésium, Croscarmellose de sodium, phosphate de dicalcium
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | Not specified | 2 Comprimé | Not specified |
Uses authorised in Canada
Helps to enhance calcium absorption and retention.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
If symptoms persist, consult a health care practitioner.
- Contre-indications
Do not use if pregnant or breastfeeding.
Product record
- Licence holder
- Jaapharm Canada Inc.
- NPN or DIN-HM
- 80000609
- Status
- Active licence
- Licence date
- 29 July 2005
- Revision date
- Not provided
- Form
- Comprimé
- Route of administration
- Orale
- Application type
- Officinale
Source
Official Health Canada record, licence 80000609
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “L-Lysine 400 L-Lysine HCL Tablet 400 mg (Jaapharm Canada Inc.): composition and ingredients”, https://compoatlas.com/en/supplements/canada/80000609-l-lysine-400-l-lysine-hcl-tablet-400-mg, updated 29 July 2005.